目的 观察国产苯达莫司汀+卡非佐米+地塞米松治疗复发/难治性多发性骨髓瘤(Relapse or Refractory Multiple Myeloma,RRMM)的临床疗效.方法 回顾性选取2021年10月—2023年6月在广西玉林市红十字会医院血液肿瘤科就诊的32例RRMM患者的临床资料.所有患者均使用苯达莫司汀+卡非佐米+地塞米松方案再诱导治疗.评估患者的总有效率、无进展生成期、总生存期及不良反应.结果 32例RRMM均接受国产苯达莫司汀+卡非佐米+地塞米松治疗1疗程以上,治疗中位疗程数为[4(1,8)]个,总有效率18例;≥非常好的部分缓解6例.32例患者随访中位PFS为[7.4(3.5,12.8)]个月,中位OS时间为[11.3(4.6,18.8)]个月.血液学不良反应较为常见的是中性粒细胞计数减少7例、血小板减少6例、贫血6例;非血液学不良反应中常见乏力18例、呼吸道感染6例、心脏事件5例,恶心4例及周围神经病变4例.结论 苯达莫司汀+卡非佐米+地塞米松对治疗RRMM患者是一种较好的选择,临床治疗效果较好,不良反应性较轻.
Clinical Observation on the Treatment of Recurrent/Refractory Multiple Myeloma with Domestic Bendamotine,Caffezomi,and Dexamethasone
Objective To observe the clinical efficacy of domestic Bendamustine+Caffezomi+Dexamethasone in the treatment of relapsed/refractory multiple myeloma(RRMM).Methods Retrospective selection of clinical data of 32 pa-tients with Relapse or Refractory Multiple Myeloma(RRMM)who attended the Department of Hematology and Oncol-ogy,Yulin Red Cross Hospital,Guangxi,China,from October 2021 to June 2023.All patients were treated with a re induction regimen of bendamustine,cabozomib,and dexamethasone.Assess the overall response rate(ORR),progres-sion free survival(PFS),overall survival(OS),and adverse reactions of patients.Results 32 cases of RRMM were all treated with domestic Bendamustine+Caffezomi+Dexamethasone for more than one course,with a median treatment course of[4(1,8)]and a total effective rate(ORR)of 18 cases Very good partial remission(VGPR)in 6 cases.The me-dian follow-up PFS of 32 patients was[7.4(3.5,12.8)]months,and the median OS time was[11.3(4.6,18.8)]months.The most common adverse reactions in hematology were a decrease in neutrophil count in 7 cases,thrombocytopenia in 6 cases,and anemia in 6 cases;Among non hematological adverse reactions,18 cases were commonly associated with fatigue,6 cases with respiratory infections,5 cases with cardiac events,4 cases with nausea,and 4 cases with pe-ripheral neuropathy.Conclusion Bendamotine+Caffezomi+Dexamethasone is a good choice for the treatment of RRMM patients,with good clinical efficacy and mild adverse reactions.
NETL
NSTL
万方数据
维普
